Theravance Biopharma Inc
TBPH | NASDAQ
$17.05
+$0.03 (+0.18%)
At close: Sep 21, 2026, 4:00 PM ET
$17.05
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 107.46M | 64.38M | 57.42M | 51.35M | 55.31M | 71.86M |
Cost of Revenue | 5.52M | 37.64M | 40.62M | 63.39M | 193.66M | n/a |
Gross Profit | 101.95M | 26.74M | 16.8M | -12.05M | -138.35M | 71.86M |
Operating Income | -13.25M | -46.95M | -56.04M | -91.96M | -257.78M | -297.63M |
Interest Income | n/a | 4.88M | 9.12M | 8.55M | 1.11M | 4.44M |
Pretax Income | 129.25M | -44.61M | -49.27M | -92.82M | -265.22M | -303.34M |
Net Income | 105.9M | -56.42M | -55.19M | 872.13M | -199.43M | -278.02M |
Selling & General & Admin | 73.65M | 69.17M | 70.45M | 67.07M | 99.3M | 108.53M |
Research & Development | 37.41M | 38.05M | 46.34M | 70.07M | 201.55M | 260.95M |
Other Expenses | 4.13M | -33.54M | -43.96M | -57.24M | -181.41M | n/a |
Operating Expenses | 115.2M | 73.69M | 72.84M | 79.91M | 119.44M | 369.48M |
Interest Expense | 2.46M | 2.55M | 2.35M | 6.37M | 8.55M | 8.55M |
Selling & Marketing Expenses | n/a | 4.3M | 5.1M | 8M | n/a | n/a |
Cost & Expenses | 120.71M | 111.33M | 113.46M | 143.3M | 313.1M | 369.48M |
Income Tax Expense | 23.35M | 11.8M | 5.92M | 9K | -151K | -8.52M |
Shares Outstanding (Basic) | 50.32M | 48.85M | 55.3M | 73.59M | 69.46M | 62.35M |
Shares Outstanding (Diluted) | 51.51M | 48.85M | 55.3M | 73.59M | 69.46M | 62.35M |
EPS (Basic) | 2.10 | -1.15 | -1 | -1.26 | -2.87 | -4.46 |
EPS (Diluted) | 2.06 | -1.15 | -1 | -1.26 | -2.87 | -4.46 |
EBITDA | 137.22M | -38.45M | -51.65M | -76.08M | -232.83M | -287.82M |
EBIT | 131.71M | -42.07M | -53.65M | -79.12M | -237.64M | -294.8M |
Depreciation & Amortization | 5.52M | 3.62M | 2M | 3.04M | 4.81M | 6.97M |
Add to Watchlist
Select watchlists to add or remove TBPH